argenx is running clinical trials for a range of autoimmune diseases.
Each day at argenx, we are motivated to pursue a better tomorrow alongside patients. We aim to do this through partnership because we know that "together we are better". As your ally, we pioneer innovations to advance the understanding of rare diseases; we want to deliver immunology treatments to patients worldwide.
We listen to patients, supporters and advocacy communities; we hear your stories and share your determination.
We integrate your aspirations into how we innovate, how we conduct research and design trials, and how we can support you in the daily struggles you face living with a rare disease.
There is a common purpose across argenx that is driven by your resilience and we welcome this opportunity to be with you on this journey.
The immune system is the body’s defense system against infection and other diseases. In the case of autoimmune diseases, the immune system mistakenly identifies part of its own body as an invader and produces antibodies to attack its tissues and cells. In many cases, it is not known what causes the immune system to initiate this autoimmune response.
Examples of autoimmune diseases argenx is researching are myasthenia gravis, immune thrombocytopenia, chronic inflammatory demyelinating neuropathy and pemphigus vulgaris.
In each of these diseases, a particular type of antibody called IgG (immunoglobulin G) are often the cause of the disease.
Myasthenia Gravis (MG)
MG is a rare, neuromuscular disorder where IgG antibodies damage the communication between nerves and muscles leading to muscle weakness that can be severe and have a significant impact on patients’ lives.
Immune Thrombocytopenia (ITP)
ITP is a rare, often chronic bleeding disorder. In many cases, IgG antibodies cause reduced numbers of platelets (cells that stop or prevent bleeding) which can lead to an increased risk of bleeding and bruising, and an impaired quality of life due to fear and fatigue.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
CIDP is a rare neuropathy where damage to peripheral nerves, which may be caused by antibodies, results in progressive weakness and a loss of feeling in the arms and legs that can significantly impair a patient’s function.
Pemphigus Vulgaris (PV)
PV is a rare, chronic and severe disorder where antibodies damage the connections within the skin and cause patients to develop blisters in the skin and other body surfaces, including in the mouth, nose and eyes.
Bullous Pemphigoid (BP)
BP is the most common of the group of pemphigoid diseases and is characterized by autoantibodies against structural proteins of the dermal-epidermal junction and, clinically, by tense blisters and erosions of skin or mucous membranes close to the skin surface. The disease has a strong impact on a person’s quality of life and has a high mortality.
Idiopathic inflammatory myopathies (IIM) is the name for a group of rare, severe autoimmune disorders mediated by autoantibodies and characterized by chronic muscle inflammation, muscle weakness, pain and impaired quality of life. Myositis subsets mediated by autoantibodies include immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and dermatomyositis (DM).
Multifocal Motor Neuropathy (MMN)
MMN is a serious, debilitating autoimmune disease driven by IgM autoantibodies activating the complement pathway. The disease is characterized by a slowly progressive muscle weakness due to motor neuron degeneration which can lead to muscle atrophy characterized by wrist drop or foot drop. The disease significantly impacts a person’s quality of life.
argenx is running clinical trials of efgartigimod, in development for a range of severe autoimmune diseases. For more info on clinical trials with efgartigimod, please click the link below.
argenx is committed to improving the lives of people suffering from severe autoimmune diseases and cancer. We aim to do this in partnership; by listening to patients, supporters and advocacy communities and hearing your stories. It is your words and your resilience that motivate us to advance the understanding of rare disease and work to deliver new treatments to as many patients as possible.
While we believe participation in a clinical trial is the most appropriate way to access investigational therapies, we understand that this is not possible for all patients. In these circumstances, argenx may consider making investigational therapies available outside of a clinical trial.
This is typically done through a pre-approval access program. Click below to learn about pre-approval access to argenx investigational therapies.
Join us on this journey! Be part of this meaningful research to better understand the lives of people living with myasthenia gravis (MG).
MyRealWorld™ MG is a global observational study expected to launch in 9 countries and up to 2000 patients. Click the button below to go to the MyRealWorld™ MG website.